Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.

International journal of oncology - 1 Dec 2010

Wang Biyun, Kokhaei Parviz, Mellstedt Håkan, Liljefors Maria

Abstract excerpt

Fcγ receptors (FcγRs) on effector cells are of importance for mediating antibody-dependent cellular cytotoxicity (ADCC). FcγRIIIa158valine (V)/phenylalanine (F) and FcγRIIa131histidine (H)/arginine(R) polymorphisms have been shown to relate to prognosis in antibody-treated patients. The aim of the present study was to analyze the polymorphisms of both FcγRIIIa and FcγRIIa in colorectal carcinoma (CRC) patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Carcinoembryonic Antigen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carcinoma

Share to Colorectal Neoplasms

Share to Immunization, Passive

Share to Prognosis

Share to Receptors, IgG

Share to Treatment Outcome

Source

Identifiers

PMID: 21042730
DOI: 10.3892/ijo_00000814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.PMID 21042730Read ↗

Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.Semantic proximity Read ↗

Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy.Semantic proximity Read ↗

Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?Semantic proximity Read ↗

Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.Semantic proximity Read ↗

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.Semantic proximity Read ↗

FcγRIIa and FcγRIIIa polymorphisms and cetuximab benefit in the microscopic disease.Semantic proximity Read ↗

Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.Semantic proximity Read ↗

FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.Semantic proximity Read ↗

Ex vivo antibody-dependent cellular cytotoxicity inducibility predicts efficacy of cetuximab.Semantic proximity Read ↗

Tumour antigen targeted monoclonal antibodies incorporating a novel multimerisation domain significantly enhance antibody dependent cellular cytotoxicity against colon cancer.Semantic proximity Read ↗

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.Semantic proximity Read ↗

Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.